Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial

12 major claims checked against the paper's own evidence: all adequately supported.

Recomputed 20 tests: 18 consistent, 2 inconsistent, 20 via agent-written checks.

2 integrity concerns flagged (0 high).

5 copyedit issues flagged: mostly clarity, grammar, consistency.

Checked 57 references: 2 verified — 55 unresolved.

3 data/code links checked; 3 live.

The published paper is methodologically sound but has several reporting gaps that an informed reader should weigh: the open-label comparator, missing assumption verification, two inconsistent p-values, and no code sharing. These issues do not invalidate the primary findings but warrant a correction or independent re-analysis for the inconsistent p-values.

1. 1.
   HIGHstatistics

   In the Results section, correct the two inconsistent p-values: for adverse events (tirzepatide vs placebo) the reported p=1e-10 should be p=0.00096; for discontinuation due to AE the reported p=0.1 should be p=0.67.

   The statistics verification component found these p-values to be inconsistent with recomputed values, which could indicate a reporting error.
2. 2.
   HIGHreporting

   In the Methods (Statistical methods), add a statement verifying that the assumptions of ANCOVA (normality of residuals, homogeneity of variance) were checked, or note that robust standard errors were used.

   Standard reporting expectations for ANCOVA require assumption verification; its absence is a common reviewer objection.
3. 3.
   HIGHdata code

   Add a code sharing statement to the Data availability section, and deposit the SAS analysis scripts (e.g., for the primary ANCOVA and MMRM) in a public repository (e.g., GitHub, Zenodo) with a persistent DOI.

   Reproducibility requires access to the analysis code; the current paper provides no code sharing statement.
4. 4.
   HIGHreporting

   In the Methods (Procedures), explicitly state the manufacturer/source for tirzepatide, liraglutide, and placebo (e.g., 'Eli Lilly and Company, Indianapolis, IN, USA').

   The source of investigational products is essential for reproducibility; currently it is only implied by the funding disclosure.
5. 5.
   HIGHreporting

   In the Methods (Randomization and masking), describe the method used to generate the randomization table (e.g., computer-generated random number sequence) and who generated the allocation sequence.

   A vague description of the randomization method reduces transparency and confidence in the allocation concealment.
6. 6.
   HIGHreporting

   In the Methods (Statistical methods), pre-specify the approach for handling outliers (e.g., exclusion based on predefined SD thresholds or sensitivity analyses).

   The absence of a pre-specified outlier handling plan weakens the analytic rigor.
7. 7.
   MEDIUMreporting

   In Table 2, clarify whether the reported percentage change (e.g., −72.4% for tirzepatide at week 6) is the median percent change from baseline or the LS mean percent change, and place it in a separate column.

   The copyedit report flagged this as confusing; the percentage appears inconsistent with the absolute change if interpreted as an LS mean.
8. 8.
   MEDIUMreporting

   In the Results (Primary outcome), specify the figure references: 'Fig. 2b and Extended Data Fig. 1' instead of the ambiguous 'Fig. and Extended Data Fig.'.

   The copyedit report noted that the figure references are ambiguous without specific labels.
9. 9.
   MEDIUMreporting

   In the Abstract, consider specifying the direction of impact for tirzepatide on food intake (e.g., 'by reducing appetite and food cravings').

   The copyedit report suggested this minor clarity improvement.
10. 10.
    MEDIUMreporting

    In the Abstract footnote for VAS, rephrase 'A higher overall appetite score indicated lower appetite' to 'A higher overall appetite score indicates less appetite' for clarity.

    The copyedit report noted this is a clarity improvement.
11. 11.
    MEDIUMreporting

    In the Author contributions, change 'approved of this paper to be submitted for publication' to 'approved this paper for submission'.

    The copyedit report flagged this as a minor grammar issue.
12. 12.
    LOWreporting

    For p-values reported as '<0.0001', consider providing the exact value to four decimal places in supplementary tables to enable precise assessment of significance.

    Exact p-values are preferred for transparency, though '<0.0001' is acceptable for very small values.
13. 13.
    LOWreporting

    In the limitations section, explicitly recommend that future studies with balanced sex representation investigate sex-specific effects, given the sex imbalance across treatment groups.

    The sex imbalance is already acknowledged; a specific recommendation would strengthen the discussion.